ProShare Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-18,385
| Closed | -$70K | – | 1693 |
|
|
2020
Q1 | $70K | Sell |
18,385
-14,467
| -44% | -$62.3K | ﹤0.01% | 1102 |
|
|
2019
Q4 | $167K | Sell |
32,852
-2,633
| -7% | -$13.9K | ﹤0.01% | 1632 |
|
|
2019
Q3 | $179K | Sell |
35,485
-615
| -2% | -$3.07K | ﹤0.01% | 1464 |
|
|
2019
Q2 | $223K | Sell |
36,100
-4,227
| -10% | -$20.4K | ﹤0.01% | 1381 |
|
|
2019
Q1 | $187K | Buy |
40,327
+408
| +1% | +$1.85K | ﹤0.01% | 1489 |
|
|
2018
Q4 | $168K | Sell |
39,919
-6,959
| -15% | -$35.4K | ﹤0.01% | 1407 |
|
|
2018
Q3 | $294K | Buy |
46,878
+3,747
| +9% | +$28.8K | ﹤0.01% | 1372 |
|
|
2018
Q2 | $347K | Sell |
43,131
-578
| -1% | -$4.41K | ﹤0.01% | 1297 |
|
|
2018
Q1 | $326K | Sell |
43,709
-6,787
| -13% | -$45.1K | ﹤0.01% | 1278 |
|
|
2017
Q4 | $300K | Buy |
50,496
+4,686
| +10% | +$28.5K | ﹤0.01% | 1388 |
|
|
2017
Q3 | $337K | Buy |
45,810
+2,467
| +6% | +$15.7K | ﹤0.01% | 1098 |
|
|
2017
Q2 | $294K | Sell |
43,343
-3,688
| -8% | -$27.2K | ﹤0.01% | 1178 |
|
|
2017
Q1 | $444K | Sell |
47,031
-10,428
| -18% | -$104K | ﹤0.01% | 1046 |
|
|
2016
Q4 | $496K | Buy |
57,459
+6,445
| +13% | +$47.6K | 0.01% | 1085 |
|
|
2016
Q3 | $323K | Sell |
51,014
-9,572
| -16% | -$57.9K | ﹤0.01% | 1119 |
|
|
2016
Q2 | $256K | Buy |
60,586
+387
| +0.6% | +$1.87K | ﹤0.01% | 1284 |
|
|
2016
Q1 | $262K | Sell |
60,199
-6,077
| -9% | -$27.1K | ﹤0.01% | 1271 |
|
|
2015
Q4 | $406K | Buy |
66,276
+6,481
| +11% | +$42.5K | ﹤0.01% | 1136 |
|
|
2015
Q3 | $342K | Sell |
59,795
-4,641
| -7% | -$35.6K | ﹤0.01% | 1095 |
|
|
2015
Q2 | $481K | Sell |
64,436
-5,042
| -7% | -$30.5K | 0.01% | 1114 |
|
|
2015
Q1 | $415K | Buy |
69,478
+8,706
| +14% | +$54.8K | ﹤0.01% | 1278 |
|
|
2014
Q4 | $459K | Sell |
60,772
-2,450
| -4% | -$14.7K | 0.01% | 1247 |
|
|
2014
Q3 | $328K | Sell |
63,222
-12,588
| -17% | -$62.7K | ﹤0.01% | 1661 |
|
|
2014
Q2 | $327K | Sell |
75,810
-45,842
| -38% | -$175K | ﹤0.01% | 1847 |
|
|
2014
Q1 | $498K | Buy |
121,652
+90,492
| +290% | +$463K | 0.01% | 1874 |
|
|
2013
Q4 | $166K | Sell |
31,160
-27,855
| -47% | -$123K | ﹤0.01% | 1272 |
|
|
2013
Q3 | $297K | Buy |
59,015
+19,563
| +50% | +$106K | 0.01% | 1907 |
|
|
2013
Q2 | $176K | Buy |
+39,452
| New | +$177K | ﹤0.01% | 2088 |
|
Other funds holding PGNX
ProShare Advisors's PGNX Position: Q2 2020 in Review
ProShare Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 18,385 shares — an estimated $70K sold.
ProShare Advisors first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $498K in Q1 2014. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- ProShare Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- ProShare Advisors sold 18,385 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $70K.
- ProShare Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
- ProShare Advisors's Progenics Pharmaceuticals Inc position peaked at $498K in Q1 2014.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on ProShare Advisors's 13F filing for Q2 2020, filed 3 Aug 2020.